4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Evotec SE (EVT) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Hamburg, Germany with about 4,461 employees. Its market capitalization is roughly €547 million. In the fiscal year ended 2025-12-31, EVT reported €788M in revenue and (€104M) in net income.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Interactive charts & full statements → Open the EVT valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | €788M | €797M | €781M | €751M | — |
| Gross Profit | €114M | €115M | €175M | €174M | — |
| Operating Income (EBIT) | (€56M) | (€79M) | (€27M) | €21M | — |
| Net Income | (€104M) | (€196M) | (€84M) | (€176M) | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Total Revenue | €144M | €157M | €253M | €164M | €171M | — |
| Gross Profit | (€2M) | (€2M) | €78M | (€0M) | €9M | — |
| Operating Income (EBIT) | (€89M) | (€46M) | €37M | (€45M) | (€29M) | — |
| Net Income | (€47M) | (€122M) | €15M | (€43M) | (€44M) | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | €0M | €0M | €0M | €0M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Dividends Paid | €0M | €0M | €0M | €0M | €0M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | €1.7B | €1.9B | €2.3B | €2.3B | — |
| Total Liabilities | €900M | €960M | €1.1B | €1.1B | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EVT viewer.
About TickerBase · Data methodology & sources · Privacy · Terms